425: Aimfinity Finalizes Underwriter Debt Settlement and Loan Conversions Ahead of Docter Merger, Reveals Pro Forma Equity

Aimfinity Investment Corp. I has finalized agreements to settle deferred underwriting commissions with cash and shares, and provided updated pro forma financial estimates, as it moves closer to its business combination with Docter Inc.

Summary

• Aimfinity Investment Corp. I (AIMUF) entered into Satisfaction and Discharge of Indebtedness Agreements with D. Boral Capital LLC and US Tiger Securities, Inc., the underwriters of its initial public offering.
• The total deferred underwriting commission of $2,817,500 will be settled by each underwriter receiving $80,000 in cash and 132,875 ordinary shares of the Purchaser (PubCo Ordinary Shares), valued at $10.00 per share, totaling $1,328,750 in shares for each underwriter.
• An adjustment provision ensures that if the volume weighted average price (VWAP) of PubCo Ordinary Shares falls below $10.00 per share before the registration statement filing, the Company will compensate underwriters with additional cash or shares.
• The business combination between AIMUF and Docter Inc. involves AIMUF merging into Aimfinity Investment Merger Sub I (PubCo), and Aimfinity Investment Merger Sub II, Inc. merging into Docter, with PubCo to be renamed Inkwater Holding Inc. upon consummation.
• The business combination is scheduled to close on or about June 28, 2025.
• Purchaser also entered into a securities purchase agreement to acquire Inkrock Holding Limited, a company controlled by AIMUF's CEO and Chairman I-Fa Chang, in exchange for 687,054 Purchaser ordinary shares at $10.00 per share.
• Approximately $2.6 million in AIMUF's extension and working capital loans outstanding as of June 30, 2025, including up to $1.5 million from I-Fa Chang, will be converted into PubCo units or shares at $10.00 per unit/share.
• Approximately $0.6 million in Docter's promissory notes outstanding will be converted into PubCo Ordinary Shares at $10.00 per share by Docter Note Holders, including Mr. Hsin-Ming Huang (CEO of Docter) and Ms. Yi-Jun Ye.
• Pro forma shareholders' equity is estimated at approximately US$4.02 million as of June 30, 2025, after accounting for redemptions of 1,072,957 Class A ordinary shares, the Inkrock acquisition, loan conversions, and the underwriting commission settlement.

Sentiment

Score: 5

Explanation: The document indicates progress towards the business combination, which is positive for the SPAC. However, the significant share dilution from the underwriting commission settlement, Inkrock acquisition, and loan conversions, coupled with the adjustment provision for underwriters, introduces notable risks and potential negative impacts on existing shareholder value. The pro forma equity is also relatively small. Overall, it presents a mixed outlook, balancing merger progression with dilution concerns.

Positives

• The settlement of the deferred underwriting commission with a significant equity component ($2,657,500 out of $2,817,500) reduces immediate cash outflow for the Company at closing, preserving liquidity.
• The business combination with Docter Inc. is progressing towards its scheduled closing date of June 28, 2025, indicating forward momentum for the SPAC.
• The conversion of outstanding loans from both AIMUF and Docter into equity strengthens the combined entity's balance sheet by reducing debt obligations.

Negatives

• The issuance of 265,750 PubCo Ordinary Shares to underwriters for the deferred commission, plus 687,054 shares for the Inkrock acquisition, and additional shares for loan conversions, will result in significant dilution for existing shareholders.
• The adjustment provision for the underwriting commission settlement means that if the PubCo share price drops below $10.00, the Company may need to issue even more shares or pay additional cash, leading to further potential dilution or cash drain.
• The pro forma shareholder equity of approximately US$4.02 million as of June 30, 2025, after redemptions and adjustments, is relatively modest for a publicly traded entity, indicating a smaller post-merger company.

Risks

• Risks related to the expected timing and likelihood of completion of the proposed business combination, including the risk that closing conditions may not be satisfied or waived, or regulatory approvals may not be obtained on a timely basis.
• Risks related to the ability of AIMUF and Docter to successfully integrate their businesses post-merger.
• The occurrence of any event, change, or other circumstances that could lead to the termination of the applicable transaction agreements.
• The risk of a material adverse change with respect to the financial position, performance, operations, or prospects of Docter or AIMUF.
• Risks related to disruption of management time from ongoing business operations due to the proposed transaction.
• The risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMUF's securities.
• The risk that the proposed transaction and its announcement could adversely affect Docter's ability to retain customers, key personnel, and maintain relationships with suppliers and customers.
• Risks relating to the health monitoring device industry, including governmental regulatory and enforcement changes, market competitions, and competitive product and pricing activity.
• Risks relating to the combined company's ability to enhance its products and services, execute its business strategy, expand its customer base, and maintain stable relationships with its business partners.

Future Outlook

The Company anticipates the business combination with Docter Inc. to close on or about June 28, 2025. Following the closing, the Purchaser (PubCo) will be renamed Inkwater Holding Inc. The Company is committed to filing a registration statement for the newly issued PubCo Ordinary Shares within 30 days of the closing and will use commercially reasonable efforts to ensure its effectiveness with the SEC. An adjustment mechanism is in place to compensate underwriters if the share price falls below the agreed-upon value prior to the registration statement filing.

Management Comments

• I-Fa Chang, CEO and Chairman of Aimfinity Investment Corp. I, has agreed to transfer all issued and outstanding shares of Inkrock Holding Limited (a company he controls) to Purchaser in exchange for 687,054 ordinary shares of Purchaser.
• Mr. Chang also agreed to convert up to $1.5 million of extension loan and working capital loan into units of the Company at $10.00 per unit, and convert all remaining working capital and extension loans (estimated at $1.1 million) into PubCo Ordinary Shares at $10.00 per share at Closing.
• Mr. Hsin-Ming Huang, CEO of Docter and Horn Enterprise, along with Ms. Yi-Jun Ye, agreed to convert all outstanding principal and interest of loans owed by Docter or Horn Enterprise into PubCo Ordinary Shares at $10.00 per share at Closing.

Industry Context

The business combination involves Docter Inc., which operates in the health monitoring device industry. The filing highlights general industry risks such as governmental regulatory and enforcement changes, market competitions, and competitive product and pricing activity, which are common considerations for companies in this sector.

Related Party Transactions

• Acquisition of Inkrock Holding Limited from Inkrock Holding Limited, a British Virgin Islands business company controlled by AIMUF's CEO and Chairman I-Fa Chang, in exchange for 687,054 Purchaser ordinary shares.
• Conversion of up to $1.5 million of extension loan and working capital loan from Mr. I-Fa Chang into units/shares of the Company.
• Conversion of outstanding principal and interest of loans owed by Docter or Horn Enterprise from Mr. Hsin-Ming Huang (CEO of Docter and Horn Enterprise) into PubCo Ordinary Shares.

Stakeholder Impact

• **Shareholders**: Will experience significant dilution due to the issuance of new shares for deferred underwriting commissions, the Inkrock acquisition, and the conversion of various loans into equity. The pro forma equity is also relatively small post-redemptions.
• **Underwriters (D. Boral Capital LLC and US Tiger Securities, Inc.)**: Will receive a mix of cash and equity for their deferred commissions, with a protective adjustment provision if the share price declines, ensuring their compensation value.
• **Loan Holders (I-Fa Chang, Hsin-Ming Huang, Yi-Jun Ye)**: Will convert their outstanding loans to equity in the combined entity, becoming shareholders of PubCo.
• **Docter Inc.**: Will become a wholly-owned subsidiary of PubCo, benefiting from the SPAC merger and the conversion of its outstanding promissory notes into equity.
• **Employees**: Potential impact from business integration post-merger, as mentioned in risk factors regarding retention of key personnel.

Next Steps

• Consummation of the business combination between AIMUF and Docter Inc. on or about June 28, 2025.
• Purchaser (PubCo) to be renamed Inkwater Holding Inc. upon closing.
• Filing of a registration statement on Form F-1 for the Compensation Shares within 30 days from the Closing.
• Using commercially reasonable efforts to cause the registration statement to be declared effective by the SEC.

Key Dates

Recommendation

Keywords

SPAC, Business Combination, Merger, Aimfinity Investment Corp. I, Docter Inc., Deferred Underwriting Commission, Equity Conversion, Share Dilution, Pro Forma Financials, Inkwater Holding Inc., Health Monitoring Device Industry